Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) reported second-quarter 2026 net product revenue of approximately $13.5 million, a substantial increase from $2 million in the same period last year. The growth was primarily fueled by TONMYA, the company's recently approved treatment for fibromyalgia, which generated roughly $11 million in net sales during the quarter. TONMYA recorded 12,592 total prescriptions, a 100% sequential increase, with new patient prescriptions rising 36% and refills surging 207%. This robust performance underscores the medicine's rapid adoption since its launch.
The company also highlighted that TONMYA currently has coverage representing approximately 136 million lives across commercial, managed Medicare, and Medicaid channels. This coverage is expected to expand to about 145 million lives when a managed Medicare agreement takes effect on January 1, 2027, further broadening patient access. The commercial progress is a key indicator of the drug's potential to become a standard of care for fibromyalgia, a condition that has seen limited innovation in over a decade.
Beyond TONMYA's commercial success, Tonix continues to advance its clinical pipeline. The company has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study evaluating TNX-102 SL for major depressive disorder. Additionally, Tonix is preparing to initiate an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol. These developments highlight the company's commitment to addressing high unmet medical needs in both central nervous system (CNS) and immunology therapeutic areas.
The company ended the quarter with approximately $176.2 million in cash and cash equivalents. According to management, these resources, combined with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027. This financial runway provides a solid foundation for the company to execute on its strategic priorities, including the continued commercialization of TONMYA and the advancement of its pipeline.
Tonix Pharmaceuticals is a fully integrated, commercial-stage biopharmaceutical company focused on developing and commercializing treatments for CNS and immunology conditions. In addition to TONMYA, the company's CNS portfolio includes acute migraine products Zembrace SymTouch and Tosymra, as well as TNX-2900, which is Phase 2 ready for Prader-Willi syndrome. The immunology pipeline features TNX-4800 for Lyme disease prophylaxis and TNX-1500, a CD40 ligand inhibitor for kidney transplant rejection prevention. The company's product development candidates are investigational and have not been approved for any indication.
The strong quarterly results and pipeline progress position Tonix for continued growth, making it a notable player in the biotech sector. Investors and stakeholders can access the full press release for more details at https://nnw.fm/6Yytj.
